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Transplant recipients are prone
to experience severe illness when in-
fected with the new coronavirus dis-
ease (COVID-19). Importantly, 2 of
the initially proposed drug regimens
for the experimental treatment of this
disease, lopinavir/ritonavir and chlo-
roquine, could have serious implica-
tions on the efficacy and safety of
immunosuppressive therapy; more-
over, no information is available on
the third option, remdesivir. Timely
dose adjustment is thus crucial in these
patients, and although the drug–drug
interactions are known and monitoring
of drug levels is warranted, dosing
guidance is lacking. Therefore, this
letter highlights evidence on the rele-
vant drug–drug interactions and rec-
ommends rigorous dose adjustments.
As there are no approved treat-
ment options for severe COVID-19
symptoms, WHO experts recommen-





tion showed little benefit in a recent
randomized clinical trial,1 information
on their interaction may still be of
interest for those who continue using
them. Ritonavir is a fast and strong
inhibitor of cytochrome P450 isoform
3A (CYP3A). This enzyme limits the
uptake of numerous drugs in the intes-
tine and accelerates hepatic drug clear-
ance. The clinical consequence of
CYP3A inhibition by ritonavir is a
strong increase in the biological avail-
ability and half-life of tacrolimus and
cyclosporine. A study in healthy sub-
jects showed an extreme 57-fold high-
er tacrolimus exposure, whereas
cyclosporine exposure is less affected
with a 6-fold increase.2 Similar in-
creases in exposure were confirmed in
transplant patients with hepatitis C
infection and HIV.3,4 Sirolimus and
everolimus concentrations are also ex-
pected to increase when used in com-
bination with ritonavir, but no concise
data are available. The interaction of
sirolimus and everolimus with the
strong CYP3A inhibitor ketoconazole
led to 10- and 15-fold increases in
exposure, respectively.5,6
To prevent serious clinical tox-
icity, dose adjustment for tacrolimus
and cyclosporine is essential. When a
patient on tacrolimus treatment starts a
ritonavir-containing regimen, the ta-
crolimus dose should immediately be
lowered to 0.5 mg once per week or
0.2 mg twice per week.2 Depending on
the time after transplantation, higher
maintenance dosages (0.5–1 mg per
48 hours) may apply.7 In case of rito-
navir initiation during stable cyclo-
sporine treatment, reduction to one-
fifth of the total daily dose is recom-
mended and should be administered
once per day.2 Although sirolimus
dosage reductions to 1.5 mg per week
and 1 mg per 14 days have been
advised,8 no case reports are available
for everolimus. It is advised to fre-
quently monitor immunosuppressant
drug levels, at least right before dose
administration. As the drugs’ half-lives
are expected to increase, it could take
several weeks until trough levels are
stable (40 and 15 days for tacrolimus
and cyclosporine, respectively).2
Consequently, ritonavir discon-
tinuation requires an increase in the
immunosuppressant dosage. As ritona-
vir irreversibly inhibits CYP3A, their
interaction is assumed to slowly dissi-
pate owing to the turnover of intestinal
and hepatic CYP3A enzymes.9
Calcineurin or mechanistic target of ra-
pamycin (mTOR) inhibitor dosage
may be gradually increased by 20%
of the original dose each day after ri-
tonavir cessation, and therefore, the
original dose could be reintroduced
on the fifth day. Frequent monitoring
of trough levels is recommended to
ascertain optimal treatment.
The antimalarial drugs, chloro-
quine and hydroxychloroquine, are other
treatment options. The product informa-
tion of chloroquine mentions that chlo-
roquine increases the risk for QTc
prolongation and that combination with
cyclosporine potentially increases cyclo-
sporine levels, as 2 dated case reports
indicated a 3- to 4-fold increase in
cyclosporine exposure.10 There are no
publications available on the drug–drug
interaction of chloroquine with tacroli-
mus, sirolimus, or everolimus. As pre-
viously mentioned, CYP3A inhibition
caused a 10-fold greater increase in ta-
crolimus exposure compared with cyclo-
sporine exposure. Thus, tacrolimus
exposure might be affected by chloro-
quine in the same manner. Therefore,
we advise to be vigilant of this possible
interaction and to monitor calcineurin
and mTOR inhibitor trough levels at
both the start and discontinuation of
chloroquine treatment.
There is no information on the
possible effects of remdesivir, the third
treatment option, on CYP3A. Frequent
monitoring is needed when this drug is
administered concomitantly with an
J. G. W. Kosterink, S. P. Berger, and D. J. Touw
conceived the idea for the article on ritonavir inter-
action; M. L. Toren-Wielema and P.V. Nannan
Panday conceived the idea to research chloroquine
interaction; T. R. Zijp, M. L. Toren-Wielema, P.V.
Nannan Panday, and D. J. Touw performed the
literature research; T. R. Zijp and D. J. Touw
wrote the first draft of the manuscript; and T. R.
Zijp, M. L. Toren-Wielema, P.V. Nannan Panday,
J. G. W. Kosterink, S. P. Berger, and D. J. Touw
revised the article critically for important intellec-
tual content. All authors approved the final version
of the manuscript.
The authors declare no conflict of interest.
Copyright © 2020 The Author(s). Published by
Wolters Kluwer Health, Inc. on behalf of the
International Association of Therapeutic Drug
Monitoring and Clinical Toxicology. This is an
open-access article distributed under the terms
of the Creative Commons Attribution-Non
Commercial-No Derivatives License 4.
0 (CCBY-NC-ND), where it is permissible to
download and share the work provided it is
properly cited. The work cannot be changed
in any way or used commercially without per-
mission from the journal.
652 Ther Drug Monit  Volume 42, Number 4, August 2020
immunosuppressant, and we urge to pub-
lish any experience with this combination.
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Forensic toxicology is a complex
discipline in which the detection and
accurate measurement of substances can
have significant ramifications in legal
cases, recruitment, and employment.
Analytical measurements must be precise,
accurate, and correctly reported, and if
high standards are not maintained, there
is a strong likelihood that tragic errors will
occur. Unfortunately, there is an intrinsic
uncertainty associated with making meas-
urements, which can variously be attrib-
uted to the operator, instrumentation,
analytical method, or specimen integrity.
Although analytical bias can, to a certain
extent, be evaluated and corrected through
the appropriate validation of analytical
methods and effective quality control
procedures in routine practice, random
error cannot be completely addressed,
and it is inevitable that slightly different
results will be obtained for a specimen
analyzed several times using the same
method. In analytical toxicology, measure-
ment uncertainty can be quantified,
thereby providing a clear indication of
the variability of a measurand in repeated
measures of the same substance using the
same method, controls, and instruments.
Uncertainty is thus expressed in the form
of a dispersion value, such as a SD or a
confidence interval, and allows toxicolo-
gists to interpret results more critically.
Although the International
Organization for Standardization (ISO)
requires the measurement of uncertainty,
the methods used to calculate this
uncertainty is not imposed (ISO
15189/17025). Accordingly, the choice
of the calculation method is at the
discretion of the testing laboratories.
Moreover, diverse guidelines and meth-
odologies have been proposed for the
calculation of uncertainty.1–3
Using Nordtest’s approach,1 uncer-
tainty can be calculated based on within-
laboratory and between-laboratory repro-
ducibility through independent tests
of internal and external quality controls.
Nordtest’s flow scheme comprises
the following 6 defined steps: (1) defini-
tion of the quantity to be measured
(measurand); (2) determination of
within-laboratory reproducibility compo-
nents (Rw); (3) calculation of bias
components using certified reference ma-
terials and between-laboratory compari-
son, that is, the root mean square
of the bias values (RMSbias) and the
uncertainty of certified or nominal
values [u(Cref)]; (4) conversion of com-
ponents to standard uncertainty, that is,
the uncertainty component for within-
laboratory reproducibility [u(Rw)] and
the uncertainty component for the











, and u(bias) is the
uncertainty of bias; (5) calculation of






(6) calculation of the expanded
uncertainty (U), where U = 2 · uc, to
reach an approximate confidence interval
of 95%. However, although this approach
is the simplest means of evaluating
measurement uncertainty in forensic
toxicology because calculation procedures
are simple and external quality controls
may be provided by scientific
associations, it only produces an overall
uncertainty value and lacks information
on the individual contribution of each
source of uncertainty.
The “Guide to the Expression of
Uncertainty in Measurement” (GUM)
provides well-established alternative
guidelines for evaluating and reporting
measurement uncertainty and for a num-
ber of years has been considered a stan-
dard reference.2 Although the GUM
approach is not formally imposed, the
ISO does recommend it and has provided
additional guidelines in a recent technical
note (ISO/TS 20914:2019).4 The GUM
method for uncertainty calculation can
be itemized as follows: (1) definition of
the measurand, (2) identification of pa-
rameters likely to produce significant
uncertainty, (3) estimation of the
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